AUTHOR=Huang Xiaoye , Liu Yuchun , Zhong Chuyang , Lin Zengrui , Zheng Binyun 

TITLE=Association between serum albumin-to-creatinine ratio and clinical outcomes among patients with ST-elevation myocardial infarction after percutaneous coronary intervention: a secondary analysis based on Dryad databases

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1191167

DOI=10.3389/fcvm.2023.1191167

ISSN=2297-055X

ABSTRACT=Background: The prognostic value of serum albumin to creatinine ratio (sACR) in patients with ST-elevation myocardial infarction (STEMI) remains unclear. This present study aimed to investigate the impact of sACR on incident major adverse cardiovascular events (MACE) among revascularized STEMI patients at long-term follow-up. 
Methods: A total of 461 STEMI patients who underwent successful primary percutaneous coronary intervention (PCI) were enrolled to explore the association between sACR and MACE during a 30-month follow-up. The Cox regression proportional hazard model were conducted to evaluate the prognostic value of sACR. Heterogeneity among specific groups was investigated by subgroup analysis.
Results: 118 patients developed MACE during the follow-up. A negative association between sACR and MACE was found after adjusting with other MACE-related risk factors. In subgroup analyses, the sACR was inversely associated with MACE in patients aged≥60 years (HR, 0.478; 95% CI, 0.292-0.784), male (HR, 0.528 95%CI, 0.327-0.851), with hypertension history (HR, 0.470; 95%CI, 0.271-0.816), and with anterior wall myocardial infarction (HR, 0.418; 95%CI, 0.239-0.730). Meanwhile, the negative association between sACR and MACE remained significant in sensitivity analysis that excluded patients with low serum albumin level (HR, 0.553; 95%CI, 0.356-0.860). 
Conclusions: STEMI patients who underwent successful PCI with low sACR had a higher risk of developing MACE, indicating that sACR could be used to identify STEMI patients who were at high risk of MACE.